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Abstract
Mucosal transmission of the human immunodeficiency virus (HIV) results in a bottleneck in viral genetic diversity.
Gnanakaran and colleagues used a computational strategy to identify signature amino acids at particular positions in
Envelope that were associated either with transmitted sequences sampled very early in infection, or sequences sampled
during chronic infection. Among the strongest signatures observed was an enrichment for the stable presence of histidine
at position 12 at transmission and in early infection, and a recurrent loss of histidine at position 12 in chronic infection. This
amino acid lies within the leader peptide of Envelope, a region of the protein that has been shown to influence envelope
glycoprotein expression and virion infectivity. We show a strong association between a positively charged amino acid like
histidine at position 12 in transmitted/founder viruses with more efficient trafficking of the nascent envelope polypeptide to
the endoplasmic reticulum and higher steady-state glycoprotein expression compared to viruses that have a non-basic
position 12 residue, a substitution that was enriched among viruses sampled from chronically infected individuals. When
expressed in the context of other viral proteins, transmitted envelopes with a basic amino acid position 12 were
incorporated at higher density into the virus and exhibited higher infectious titers than did non-signature envelopes. These
results support the potential utility of using a computational approach to examine large viral sequence data sets for
functional signatures and indicate the importance of Envelope expression levels for efficient HIV transmission.
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Introduction
Human immunodeficiency virus (HIV) in acutely infected
individuals is markedly less diverse genetically than in chronically
infected individuals [1] [2,3,4,5,6] [7]. Despite the fact that HIV
exists in chronic infection as a swarm of genetically related but
distinct viruses, called a quasispecies, approximately 80% of new
heterosexually transmitted HIV infections are established by a
single genetic variant of the virus [8,9]. The selection of the
transmitted founder virus is known to antedate the evolution of
selective pressure from an adaptive immune response [10], and
likely reflects constraints imposed upon the virus either during
transmission or early expansion.
Determining how one or a few of the many viral sequences from
the infecting individual successfully establish infection in the new
host may elucidate crucial events that occur during mucosal
transmission of HIV. Two general mechanisms for this genetic
bottleneck have been suggested: either it is the result of a very low
probability stochastic event whereby on average only a single virus
slips through in a random fashion, or there is active selection for
viral variants with specific biological properties, excluding the vast
majority of quasi-species. In the two largest studies of sequences
from acutely transmitted virus to date, the proportion of
individuals infected by a single genetic variant in comparison to
multiple variants did not conform to a Poisson distribution. The
authors concluded from this finding that genetic constriction at
transmission was not likely due simply to a very low probability
stochastic event [9], but that active processes were required to
produce the observed distribution of multiple versus single virus
transmissions [9].
If genetic constriction at transmission results from the active
selection of specific viral amino acid sequences, early stages in viral
transmission and expansion must favor these selected sequences
for interactions with specific extracellular receptors or intracellular
co-factors. In fact, this has been shown to be true, as there is a
strong preference for transmission of CCR5 tropic over CXCR4
tropic strains of virus [11] [12,13]. A likely candidate HIV protein
to harbor such signatures would be the viral envelope, the initial
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extracellular milieu.
Previous investigation of small sample sizes of early HIV
envelopes has failed to detect conclusive commonalities in
mutational patterns between transmitted envelopes from different
patients [4,11,14], although more recent studies have shown that
viruses with shorter loop lengths and few potential N linked
glycosylation sites are enriched among transmitted viruses [15]. A
comparison of envelope sequences of acutely infected individuals
and chronically infected individuals was recently completed based
on a much larger sample size. Consensus envelope amino acid
sequences from forty-three acutely infected individuals were
compared to forty-eight consensus sequences from chronically
infected individuals, using previously described phylogenetically
controlled methods [16]. A hold out set of comparable size was
reserved to validate signatures defined in the original data
(Gnanakaran, et al., manuscript under review).
Potential signatures were identified at or near the CCR5 co-
receptor binding site and the CD4 binding site, as well as at amino
acid positions 413–415, where transmitted viruses exhibited loss of
a potential N-linked glycosylation site that has previously been
associated with escape from broadly neutralizing antibodies. The
amino acid position that showed the most dramatic and
statistically significant difference between acute/early and chronic
envelopes in both the initial and validation analysis was amino
acid position 12 of the envelope glycoprotein. Position 12 is
variable; within the B clade as well as most other clades, a histidine
is the most common amino acid at this position (Gnanakaran, et
al, manuscript under review). The amino acid residue at this
position was statistically more likely to be stably preserved as
histidine in envelopes of acutely transmitted viruses, and was more
likely to acquire a different amino acid than histidine in envelopes
of viruses from chronically infected individuals. The recurrent
pattern of mutation away from histidine during the course of
infection suggests that it may be commonly selected against as
infections progress. The high frequency of histidine among acute
and early viruses, however, demonstrates that viruses carrying the
signature histidine are fit and readily transmitted, and the relative
absence of the other forms may indicate selection at transmission.
Position 12 in the envelope amino acid sequence lies within the
leader peptide of the protein. The discovery of an envelope
signature at this site suggests a novel role for the leader peptide in
regulating envelope characteristics that impact on early infection.
The envelope leader peptide is primarily responsible for
directing transport of the nascent polypeptide to the endoplasmic
reticulum (ER). Unlike the leaders of other secreted and
membrane-bound proteins, it is cleaved post-translationally
instead of co-translationally, and this late cleavage has been
hypothesized to confer an unusual role for the leader in regulating
higher order processing of the envelope protein. The envelope
leader has been implicated in the timing of binding of envelope to
various ER chaperones responsible for promoting proper folding
and glycosylation of envelope, including calnexin and CD4 [17–
18] [19,20]. Substitution of the native envelope leader peptide
with certain heterologous leaders augmented expression and
secretion of envelope [21], while substitution of the leader peptide
of a heterologous protein with the envelope leader peptide slowed
ER processing of that protein by delaying folding and maturation
of glycosylation [17]. HIV envelope synthesized through heterol-
ogous leader peptides in the context of a complete provirus
resulted in decreased envelope incorporation into viral particles
and diminished in vitro infectivity [22]. These data suggested that
the signal peptide is not merely a passive trafficking signal, but
rather an evolving, active modulator of envelope function.
The present studies were initiated to examine the function of the
signal peptide signature derived computationally by Gnanakaran
and colleagues [manuscript appended]. We hypothesized that a
signature located in the leader peptide would manifest itself during
envelope synthesis as the leader is cleaved early in the biosynthesis
of the glycoprotein. We utilized HIV envelopes from acutely
infected individuals to examine the effects of polymorphisms at
position 12 on translation of envelope, leader peptide function and
viral infectivity.
Materials and Methods
Plasmid Constructs and PCR mutagenesis
Transmitted founder rev-vpu-env cassettes derived by single
genome amplification and cloned into pcDNA3.1/V5-His (Invi-
trogen) have been described [8]. Position 12 point mutants were
generated using two-step PCR. The following mutagenic primers
were utilized to introduce single base pair changes at the position
12 site converting histidine or arginine into glutamine (AA01–
AA03) or converting non-histidine residue to histidine (AC01–
AC03):
AA01: 59 CCTATGGCAGGAAGAAGCGG
39 CATCTTATAGCAAAGCCCTTTC
HDQ_F: GAGGAATTGGCAGCAATTGTGGAAA-
TGG
HDQ_R: CCATTTCCACAATTGCTGCCAATTCC-
TC
AA02: 59 CCTATGGCAGGAAGAAGTGG
39 CTTATAACAAAGCCCTTTCG
RDQ_F: GAAGAATTGTCAGCAATTGTGGAGAT-
GGG
RDQ_R: CCCATCTCCACAATTGCTGACAATTC-
TTC
AA03: 59 CCTATGGCAGGAAGAAGCGGAG
39 CTTATAGCAAAGCCCTTTCC
RDQ_F: GAGGAATTGTCAGCAATTGTGGACAT-
GGG
RDQ_R: CCCATGTCCACAATTGCTGACAATTC-
CTC
AC01: 59 CCTTAGGCATCTCCTATGGCAGG
39 GTTATAGAAGAGCCCTTTCTAAGCC
QDH_F: GAATTGTCAGCACCACTTA
QDH_R: CCATAAGTGGTGCTGACAATTC
AC02: 59 CCTATGGCAGGAAGAAACGGAGAC
39 CATCTTATAGCAAAGCCCTTTC
(gap)DH_F: GATCAGGAAGAATTACCAGCACTG-
GTGGAAATGGGGCAC
(gap)DH_R: GTGCCCCATTTCCACCAGTGCTGG-
TAATTCTTCCTGATC
AC03: 59 CCTATGGCAGGAAGAAGCGGAG
39 CATCTTATAGCAAAGCCCTTTC
QDH_F: GAAGAATTATCAGCACTGGTGGAGA-
GG
QDH_R: CCTCTCCACCAGTGCTGATAATTCTT-
C
For amplification, thermocycler conditions were 95 C for 4
minutes; 30 cycles of 95 C for 300, 50 C for 300, 72 C for 49;7 2C
for 209. In the first PCR step, the 59 (1) and 39 (2) mutated
fragments were individually generated in two separate reactions
using either (1) the 59 primer starting at the Rev start codon and
the reverse internal mutagenic primer, or (2) the forward internal
mutagenic primer and 39 Env primer, respectively. These products
were agarose gel purified, combined and introduced into a second
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second stage PCR were cloned into pcDNA3.1 by TA ligation.
V5-epitope tagged versions of transmitted envelopes were
generated by PCR using the 59 primers above and the following
39 primers to eliminate the stop codon of Env:
AA01: CAACAAAGCTCTTTCCAAGCCCTG
AA02: CAACAAAGCCCTTTCGAAGCCCTG
AA03: GAGCAAAGCCCTTTCCAAGCCCTG
AC01: GAGAAGAGCCCTTTCTAAGCCCTG
AC02: GAGCAAAGCCCTTTCAAAGCCCTG
AC03: GAGCAAAGCCCTTTCCAAGCCCTG
These PCR products were cloned in pcDNA3.1. All mutants
were verified by sequencing.
Quantification of Envelope Synthesis
293T cells obtained from the American Tissue Type Collection
were maintained in Dulbecco’s Modified Eagle Medium with 10%
fetal calf serum. Jurkat human leukemia T cell line were also
obtained from ATCC and maintained in RPMI supplemented
with 10% fetal calf serum. All cells were maintained in a
humidified incubator at 37 C with 5% carbon dioxide.
For Jurkat transfections, 2610
6 Jurkat cells were transfected
with 4 micrograms of plasmid DNA using DMRIE-C (Invitrogen)
per manufacturer’s protocols, in serum-free, antibiotics-free
medium. 10% fetal calf serum was added after 4 hours. Cells
were lysed after 48 hour incubation in 1% NP40, 20 mM Tris
pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA with
protease inhibitor cocktail (Sigma). Lysates were subjected to
SDS-PAGE using the NuPage system (Invitrogen) on a Bis-Tris 4–
12% gel run at 200 mV for 1 hour. Transfers were done using the
same system to a 0.45 micron nitrocellulose membrane. Blots were
probed with 3B3, a mouse monoclonal anti-gp120 antibody (gift of
B. Haynes), or anti-V5 antibody (Invitrogen) to assess for envelope.
Antibodies to B-actin (Santa Cruz sc-81178) and p24 (Santa Cruz
sc-69658) were used as controls.
All experiments were repeated multiple times and representative
images are shown.
The Quantity One analysis software (Bio-Rad) was used to
quantify relative band intensity on Western blot images.
P24 ELISA
An HIV-1 p24 enzyme-linked immunosorbent assay kit
(Zeptometrix) was utilized to quantify p24 in pseudovirion
supernatants. Supernatants were diluted 1:250 to 1:5000 in
protocol lysis buffer, and incubated overnight on pre-coated
plates. Plates were processed per manufacturer’s protocols, and
samples were read on a Spectramax 384 Plus at 450 nanometers.
TZM-bl Assay
Pseudovirion supernatants were serially diluted five-fold in 96-
well plates in duplicate or triplicate. 2610
4 TZM-bl cells (gift of M.
Seaman) along with 10 ug/mL of DEAE dextran were added to
each well. Samples were co-incubated for 48 hours. 100
microliters of Bright-glo reagent (Promega), containing lysis buffer
and luciferase substrate, was added to each well and samples were
incubated for 2 minutes at room temperature. Samples were
analyzed using a Perkin Elmer Victor 3 luminometer.
Luciferase reporter
We used the Ready-To-Glow Dual Secreted Reporter Assay
(Clontech) to generate and assay leader peptide reporters. We used
two-step PCR to generate HIV-1 envelope leader peptide
luciferase chimeric proteins. The first step consisted of parallel
PCR reactions. One reaction included either AA01, AC01 or the
AA01 position 12 mutant as template. Primers for the first reaction
included as the forward primer Env specific 59 leader sequence
and as reverse primer a fusion sequence composed of internal
envelope signal peptide sequence joined to 59 luciferase sequence.
The second reaction utilized the Metridia longa luciferase expression
plasmid, pMetLuc2-Control Vector, as the template. Upstream
primers for the second reaction included the reverse complement
of the fusion primers described above; downstream primers were
constructed from 39 sequence for luciferase. Primer sequences
were:
AA01: 59 ACCGGTGCAATGAGAGTGAAG
Internal_F GATCTGTAGTGCTAAGAGCACCGA-
GTTC
Internal_R GAACTCGGTGCTCTTAGCACTACA-
GATC
AC01: 59 ACCGGTGCAATGAGAGTGAAGG
Internal_F GATTTGTAGTGCTAAGAGCACCGA-
GTTC
Internal_R GAACTCGGTGCTCTTAGCACTACA-
AATC
Luciferase: 39 CGCGGCCGCTCATCACCTGTC
For the first stage of amplification, thermocycler conditions
were 95 C for 4 minutes; 30 cycles of 95 C for 300, 50 C for 300,7 2
C for 600; 72 C for 109. For second stage PCR, 1/20
th of the
volume from the leader peptide and the luciferase PCR reactions
were combined with appropriate envelope specific upstream and
luciferase specific downstream primers. For the second stage of
amplification, thermocycler conditions were 95 C for 4 minutes;
30 cycles of 95 C for 300, 50 C for 300, 72 C for 39 300; 72 C for
109. Products of the second reaction were agarose gel purified and
cloned into pcDNA3.1.
10
6 Jurkat cells were transfected in triplicate with three
micrograms of plasmid DNA of the various leader peptide-
luciferase chimeras using DMRIE-C reagent. Cells were co-
transfected with one microgram of plasmid DNA for pSEAP2-
Control Vector, expressing secreted alkaline phosphatase from its
native leader peptide.
150 microliters of each of the triplicate supernatants was
harvested at 12, 24, 36, 48 and 60 hours post transfection, without
disrupting the underlying cells. Supernatants were analyzed
separately for luciferase and SEAP activity per manufacturer’s
instructions. Chemiluminescence was measured on a Perkin Elmer
Victor 3 luminometer.
Pseudovirion generation and purification
293T cells were plated to reach 90 – 95% density in T-75 flasks
by day of transfection. Either 16 micrograms of SG3DEnv (AIDS
Reagent Program) and 4 micrograms of pcDNA3.1 envelope (four
to one ratio) or 10 micrograms (one to one ratio) of each construct
was transfected using lipofectamine 2000. Supernatants were
harvested 24 – 48 hours later and 0.2 micron filtered. These were
used either directly in the TZM-bl assay or subsequently clarified
by centrifugation at 4,000 RPM for 30 minutes followed by
ultracentrifugation over 20% sucrose w/v in phosphate buffered
saline at 27,000 RPM for 2 hours in an SW-28 swinging bucket
rotor (Sorvall). Supernatants were decanted and pellets dried
briefly before resuspension in 50 – 100 microliters of PBS.
For quantitative Western blot, five T-75 flasks each for
pseudovirions of AA01 and AC01 were pooled prior to
ultracentrifugation. Pseudovirions were purified as above. Two-
fold serial diluted purified ConSDCFI140 (from Dr. Huaxin Liao)
and HIV-1 p24 protein (Protein Sciences Corp., CT) and of
pseudovirion samples AA01 and AC01 were resolved by SDS-
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proteins were transferred to polyvinylidene difluoride (PVDF)
membranes, incubated with PBS-T with 5% non-fat milk for
1 hour at room temperature, and then incubated with goat-anti-
gp120 antibody (USbiological, Swampscott, MA) or rabbit anti-
p24 antibody (NIH reagent program) overnight at 4uC. Protein-
bound antibody was probed with rabbit-anti-goat IgG-HRP or
goat anti-rabbit IgG-HRP (Southern Biotech, Birmingham, AL)
and developed using an enhanced chemiluminescence (ECL)
detection system (GE Healthcare, Piscataway, NJ), respectively.
The Env and gag contents were measured using the VersaDoc
4000 Imaging System (Bio-Rad, Hercules, CA). The density of
each band from the pseudovirion samples was interpolated into a
standard curve derived from a linear regression of density values
from serial dilutions of purified ConSDCFI140 or HIV-1 p24
protein.
Mathematical model
We utilized a previously published model of acute infection
studied by Nowak et al. for SIV and Stafford et al. for HIV
[23,24]. The equations in the model relate three variables: V, viral
load; T, activated, uninfected CD4+ T cells; T*, infected CD4+ T
cells. Activated, uninfected target cells are presumed to be
renewed at a constant rate, l, and die at a rate of d per cell.
Infected cells die at a rate of d, and plasma virus decays at a rate of
c. New virions are produced at a rate of p per infected cell.
Uninfected cells are infected at a rate proportional to the amount
of free virus, governed by the proportionality constant k, the
infectivity.
dT
dt
~l{kVT{dT
dT
dt
 
~kVT{dT 
dV
dt
~pT {cV
Equations for the exponential viral growth rate, r0, and the steady-
state viral load, Vss, were taken from Nowak, et al. [23]. The free
on-line software Math Mechanixs was used to graph equations.
Results
Position 12 lies within a charged domain of the leader
peptide
Leader peptide sequences of most secreted or membrane-bound
proteins are characterized by a positively charged amino terminus,
a short hydrophobic span and a carboxy terminus that culminates
in a cleavage site. The HIV envelope leader peptide, at thirty
amino acids, is longer than most leader peptides and more highly
positively charged, with on average five basic amino acids [21].
The proposed HIV envelope signature at residue 12 lies within the
positively charged N-terminus of the leader sequence. Consistent
with this, sixty-nine of seventy-nine transmitted envelopes
analyzed from the CHAVI 001 cohort contained histidine at this
position. Four of these seventy-nine leader peptides also had
arginine at this residue. We hypothesized that because arginine at
position 12 would preserve the overall positive charge of this
region of the leader, it would maintain the function of a histidine
signature. In contrast, fifty-seven out of the one hundred and
eleven analyzed chronic envelopes had an uncharged glutamine or
proline, or eliminated the charged residue altogether from position
12, leading to a change in the charge distribution of the typically
basic N-terminus of the leader. We hypothesized that non-basic
residues at position 12 found in chronic envelopes represent
evolution away from the transmission genotype.
Because of the leader peptide’s primary role in trafficking of
newly translated proteins, variation at position 12 of HIV envelope
might be expected to manifest itself phenotypically at the level of
protein synthesis. Alterations in the rate of endoplasmic reticulum
transport of gp160 early during HIV infection may result in higher
throughput envelope synthesis, potentially altering the rate of
virion production or the protein content of virions produced.
Alternatively, the envelope leader’s unusual delayed cleavage and
putative role in modulating gp160 interactions with calnexin and
other endoplasmic reticulum chaperones suggested a role for
leader peptide polymorphisms in modulating envelope structure
and glycosylation [25,26,27], potentially impacting on down-
stream envelope-host interactions.
In order to study the biochemistry of the leader peptide with the
position 12 signature, we obtained functional rev-vpu-env cassettes
from 14 acutely infected individuals as previously described [8].
These cassettes contained the env genes of transmitted/founder
HIV-1 cloned into pcDNA3.1 (Invitrogen) and contained the
entire gp160 open reading frame, including 59 sequence extending
to the Rev start codon [8]. A portion of the amino acid alignments
of the leader peptides of these sequences are shown in Table 1.
Complete nucleotide sequences for these envelopes are accessible
through GenBank (EU574937–EU579293) [8], as are all trans-
mitted and chronic envelopes used in the initial analysis that
defined the position 12 signature (Gnanakaran, et al, manuscript
under review). Characteristics of the study subjects at the time at
which viruses were isolated, including patient viral load and Fiebig
stage [28] are detailed in Table S1 and in reference [8].
Six of these envelopes were selected at random from the entire
cohort because their leader peptide sequences contained a position
12 signature histidine or a similarly basic arginine at position 12.
The remaining eight envelopes were specifically chosen because
they are atypical in the transmitted envelope cohort in that they
Table 1. Leader peptide sequences of transmitted envelopes.
Specimen
Identifier 12 Pseudo
TT31P.2F10.2792 MRVK ET KRNWQ H L-AA01
BORId9.4D7.1410 MRAK EI RKNC Q R L-AA02
TT27P.8H1.2730 MRAK EI RKNC Q R L-AA03
700010040.C9.4520 MRVMGI RKNY Q H L-AA04
PRB931_06.TC3.4930 MRVMGI RKNY Q H L-AA05
12008.08_B33_4830 MRVMEI RRNY Q H W-AA06
9021_14.B2.4567 MRVK GI RKNC Q Q HLAC01
9020.20 A13 MRVK GI RKNY -- W-AC02
PRB956.04B20 MRAT GMRKNY Q Q W-AC03
1059_09.A4.1460 MRVT EI RKNY -- L-AC04
SC33_4A4_2589 MRVK GI RRNWQ G L-AC05
SC33_4H1_2589 MRVK GI RRNWQ G L-AC06
700010058_A4_4375 MRVT GI KKNY Q N L-AC07
SUMA_2 MKVK GI RKNY -- F-AC08
Alignment of first 14 amino acids of envelope for 14 transmitted clones,
grouped by position 12 signature (bolded). Each sequence has a unique
specimen identifier as well as a pseudonym, by which it will be referred in this
paper.
doi:10.1371/journal.pone.0023673.t001
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including glutamine, glycine, asparagine, or a gap in the
alignment. There was no phylogenetic clustering of envelopes
bearing the signature distinct from those lacking the signature
(Figure 1), suggesting that the phenotypic similarities among
signature containing envelopes could not be explained by a shared
evolutionary history.
Non-signature envelopes exhibit lower steady-state
expression
We began our exploration of the effects of the position 12
polymorphism on HIV biology by examining envelope translation.
We transiently transfected Jurkat T cells with the 14 transmitted
envelope constructs described previously. Forty-eight hours after
transfection, we compared expression by Western blot, (Figure 2A).
Comparable transfection efficiencies were confirmed by co-
transfection with a GFP expression plasmid (data not shown).
We observed higher levels of steady-state envelope expression by
envelopes with a basic residue at position 12 (AA01– AA06) in
comparison to those lacking the signature (AC01 – AC08). Using
band densitometry to compare relative expression levels, we found
that, on average, signature envelope expression was 2.5-fold higher
than non-signature envelope expression; the difference in signal
intensity between the two groups was highly significant (p,.005).
A trivial explanation for the apparent differences in expression
between these groups of envelope constructs might be differences
in affinity of the anti-gp120 antibody for the different envelope
proteins. To control for this, we generated epitope-tagged versions
of three signature and three non-signature envelopes utilizing a
carboxy-terminus V5 epitope tag encoded within the pcDNA3.1
expression vector. We probed Western blots of transfections of
these constructs with an anti-V5 antibody, and again observed a
trend to reduced expression in non-signature envelopes (Figure 2B).
The acutely transmitted envelopes described above were all
isolated from different patients, and hence have significant
sequence heterogeneity throughout the envelope protein. To
demonstrate that differences in expression were due specifically to
polymorphisms at position 12, we arbitrarily selected three basic
residue-bearing envelopes, AA01, AA02 and AA03, and used site-
directed PCR mutagenesis to convert the histidine or arginine
residue into a glutamine, a relatively common amino acid variant
found at this position. We cloned these position 12 envelope
mutants into pcDNA3.1, and confirmed the integrity of the full-
length envelopes by sequencing. We expressed these position 12
mutant envelopes, and the parent envelopes, in Jurkat cells and
observed an over 60% decrement in expression associated with the
point mutations (Figure 2C).
We performed the converse experiment using three non-
signature envelopes, AC01, AC02 and AC03, and replaced the
glutamine or alignment gap at position 12 of these leader peptides
with histidine. We observed an approximately three-fold increase
in steady-state protein expression of these envelopes after mutation
of this residue (Figure 2D), confirming that a basic position 12
residue is important for optimal expression of envelope in
lymphocytes.
Non-signature leader peptide polymorphisms diminish
ER targeting
A plausible explanation for the differences in steady-state
protein expression among position 12 variants is that position 12
histidine or arginine is critical for the trafficking efficiency of the
leader peptide in certain cell types, and loss of this basic residue
results in misdirected nascent peptide and loss of fully synthesized
envelope. In general, the success of appropriate targeting of
secreted or membrane-bound proteins to the endoplasmic
reticulum appears to vary significantly between leader peptides,
with misdirected proteins locating to the cytoplasm where they are
degraded [29,30]. Furthermore, polymorphisms within endoplas-
mic reticulum targeting sequences are relevant for disease states:
an inherited mutation in the leader peptide sequence of factor VII
has been shown to result in mistargeting of the nascent polypeptide
to the cytoplasm and a reduction in overall expression of the
mature Factor VII protein; this endoplasmic reticulum-trafficking
abnormality underlies the heritable coagulation disorder associat-
ed with this mutation [31]. We thus investigated whether higher
levels of envelope translation among transmitted viruses are driven
by increased efficiency of targeting of nascent envelope to the
endoplasmic reticulum.
We employed a protein secretion reporter strategy to address
the question of whether a position 12 signature bearing leader
peptide is a more effective trafficking signal than a non-signature
leader. Heterologous reporter proteins, such as secreted alkaline
phosphatase, have been used to examine the regulation of secreted
protein synthesis, because these reporters can be detected using
standardized, rapid assays, without need for Western blot. For our
reporter, we decided to use the luciferase of the marine copepod
Metridia longa, which possesses an endoplasmic reticulum targeting
signal sequence [32]. We used fusion PCR to replace the native
Metridia longa luciferase leader peptide, MDIKVVFTLVF-
SALVQA, with the envelope leader peptides of (1) AA01; (2)
position 12 histidine to glutamine mutant of AA01; (3) AC01.
We transfected Jurkat cells with the leader peptide reporter
constructs and measured supernatant luciferase activity post-
transfection (Figure 3). We co-transfected a secreted alkaline
phosphatase (SEAP) reporter plasmid under control of a different
promoter and the native SEAP leader peptide, and measured
SEAP activity in the supernatant as a control for transfection. We
observed detectable luciferase activity for all constructs as early as
12 hours after transfection. This activity was maximal at 36 to
48 hours post-transfection, plateaued and then began to diminish
at 60 hours post-transfection. At peak and plateau, the signature
Figure 1. Maximum likelihood phylogenetic tree for envelope
sequences used in this study. Sequence alignments and ML tree
were generated using Seaview 4.0 [49]. Envelopes with the basic
position 12 residue are boxed and those lacking the signature are not
boxed.
doi:10.1371/journal.pone.0023673.g001
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activity than both the non-signature bearing envelope AC01 and
the position 12 mutant envelope, AA01-mu. A slightly lesser
magnitude difference in luciferase activity was observed at earlier
time points. These results suggest that polymorphisms at position
12 directly impact leader peptide efficiency in directing nascent
polypeptides to the endoplasmic reticulum, and that this influence
on leader function is not specific to HIV-1 envelope but can be
imparted to any secreted protein downstream of the leader.
Non-signature envelopes are less infectious in vitro
Because the leader peptide is cleaved early in the synthesis of the
HIV Envelope, any phenotype dictated by an HIV leader peptide
polymorphism should be manifest prior to or during endoplasmic
reticulum processing of gp160. If in vivo selection for a signature
occurs, there must be physiologic consequences downstream of
these biochemical alterations to envelope that are susceptible to
selection pressure. A signature imbedded in the leader peptide of
envelope could influence the quantity of glycoprotein produced
and incorporated and thus virion infectivity.
To determine the impact of position 12 polymorphisms on
virion production and infectivity, we developed an in vitro
complementation assay. By pseudotyping the transmitted enve-
lopes with a uniform set of other viral proteins, we were able to
evaluate the effects of envelope polymorphisms on virus infectivity
in isolation of other variables. We generated pseudovirus by co-
transfection of the envelope constructs with the SG3DEnv
packaging vector, at a four to one ratio of packaging vector to
Envelope. This packaging vector expresses all non-Envelope
structural and accessory proteins. We normalized harvested
supernatants by p24 ELISA and applied the supernatants to a
standard reporter cell line—the TZM-bl HeLa cell line that has
been stably modified to express CD4, CXCR4 and CCR5, and
which contains a luciferase reporter driven by an HIV-1 LTR
promoter [33]. We measured luciferase activity as a proxy for
single round infectivity of these non-replicating viruses. Relative
Figure 2. Position 12 signature enhances steady-state envelope expression in Jurkat cells. (A) Transmitted envelopes were expressed in
Jurkat cells by transient transfection and cell lysates analyzed by SDS-PAGE and Western blot, probed with the 3B3 monoclonal anti-gp120 antibody.
Equal well loading was confirmed by subsequent membrane probing with a monoclonal antibody to beta-actin. Envelope signal intensities were
quantified by Quantity One (BioRad). Mean signal for AA01–AA06: 3433 arbitrary units, standard deviation: 973. Mean and standard deviation for
AC01–AC08: 1379 and 481, respectively. P value by Students’ two-tailed T-test=.0002 for difference between the two groups. (B) Six transmitted
envelopes were carboxy-terminus V5 epitope tagged and expressed in Jurkat cells. Western blots were probed with a monoclonal antibody to V5. (C)
Single point mutations were introduced into the sequences of three envelopes, converting the native histidine or arginine (WT) into non-basic
glutamine (Mu). Mean decrement in protein expression caused by position 12 mutation was 61%, with a standard deviation of 16% among the three
envelopes analyzed. (D) Single point mutations were introduced into three envelopes converting the native glutamine or alignment gap (WT) into
basic histidine (Mu). Mean increase in protein expression caused by position 12 mutation was 3.6 fold with a standard deviation of 1.9 fold.
doi:10.1371/journal.pone.0023673.g002
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supernatant added to the reporter cells (Figure 4).
The results showed that envelopes bearing the position 12
signature were generally considerably more infectious than
envelopes with non-signature position 12 residues, the only
exception being AC06 which encoded a glycine at position 12,
yet appeared to generate the most infectious pseudovirions.
Pseudoviruses constructed using Envelopes with glutamine or a
gap in the alignment were the least infectious in this assay. We
compared luminescence of all of the histidine or arginine
containing enveloped pseudoviruses to that of the non-signature
enveloped pseudoviruses using the Mann-Whitney test; at all
dilutions of virus, the basic position 12 enveloped viruses exhibited
significantly greater infectivity than non-signature enveloped
viruses. These results indicate that the presence of histidine or
arginine residues at position 12 of a transmitted envelope is
correlated with greater in vitro pseudovirus infectivity than most
other common polymorphisms at this site. Interestingly, envelope
AC05, which has a glycine at position 12, was comparably
infectious to position 12 signature envelopes, suggesting that there
are likely other determinants of infectivity that can modify and
ameliorate the position 12 phenotype.
We next sought to determine if polymorphism at position 12 is
alone sufficient to produce differences in Envelope infectivity. We
used envelopes containing point mutations at the signature to
generate pseudovirions and assayed these in TZM-bl cells. We
found that specific mutation at position 12 from histidine to a non-
histidine residue did not substantially reduce pseudovirion
infectivity. Similarly, mutation of a position 12 non-histidine
residue to histidine was insufficient to increase pseudovirion
infectivity (data not shown). This suggests that position 12 may not
be the sole determinant of the infectivity phenotype we have
observed, but may be one component of a larger multi-locus
transmission motif.
Non-signature envelopes are incorporated at lower
density into virions
To examine envelope particle incorporation, we generated
pseudovirions with transmitted envelopes and purified these
pseudovirions by ultracentrifugation through a 20% sucrose
cushion. We quantified p24 in pelleted virus and showed no
difference in p24 incorporation associated with the position 12
polymorphism (Figure 5A). We subsequently used Western blot to
compare envelope incorporation into pseudovirions and observed
that signature-bearing envelopes were incorporated at a higher
density into pseudovirions than non-signature-bearing envelopes
(Figure 5B). The differences in envelope incorporation into
pseudovirions were consistent with the differences in protein
synthesis between the signature and non-signature envelopes we
had previously observed in Jurkat transfections.
We then attempted to quantify more precisely the ratio of
Envelope to Gag in the pseudovirions. Large quantities of AA01
and AC01 pseudovirus were prepared and purified, analyzed by
Western blot and compared to quantified standards for both
Envelope and Gag (Figure 6). For a similar quantity of p24, AA01
pseudovirions contained more than six times as much envelope as
AC01 pseudovirions. The ratio of Gag to Envelope in the
signature-containing pseudovirion was 7.5: 1, much lower that the
more commonly reported virion Gag: envelope ratios of 40 – 60:
1, whereas this ratio in the non-signature pseudovirus was 49:1.
Pseudovirions in these experiments were generated by co-
transfection of separate plasmids for envelope and for other
structural proteins, at a ratio of four to one, utilizing larger
amounts of non-envelope plasmid than envelope plasmid DNA.
We queried whether altering the ratio of transfected DNA and
consequently the ratio of translated viral envelope and Gag
proteins might affect the phenotype of the pseudovirions. We
hoped to determine whether increasing the relative quantity of
envelope in the transfection might account for the phenotypic
differences we observed between signature and non-signature
envelopes. We transfected cells with either a 1:1 or a 4:1 ratio of
SG3deltaEnv to envelope plasmid and purified the pseudovirions.
We analyzed similar quantities of pelleted virus for envelope, p24
incorporation and single round infectivity (Figure 7). Envelope
incorporation was not altered by modulation of the ratio of
transfected DNA. The discrepancy in envelope incorporation
between signature and non-signature pseudovirions was similar at
both transfection ratios. In contrast, p24 incorporation was
reduced by four to five fold at a transfection ratio of 1:1 in
comparison to a transfection ratio of 4:1. This was true for both
signature and non-signature pseudovirions. These results suggest
that envelopes with the position 12 signature were incorporated at
higher density into virions.
Computational Model of Infectivity in Early and Late
Infection
One intuitively straightforward hypothesis regarding why a
signature that associates with infectivity of HIV in vitro may be
Figure 3. Position 12 polymorphism influences efficiency of
leader peptide in regulating protein transport through the
secretory pathway. Secreted luciferase reporter constructs were
generated to help quantify leader peptide efficiency. Fusion PCR was
utilized to substitute the 31 base pair leader peptide of HIV-1 envelope
for the 18 base pair Metridia longa secreted luciferase leader peptide.
Secreted luciferase constructs were generated bearing the leader
peptides of envelopes AA01, AC01 and AA01-Mu containing the
histidine to glutamine mutation. These were co-transfected in triplicate
into Jurkat cells with a human secreted alkaline phosphatase control
vector (pSEAP2, Clontech). Culture supernatants were collected at 12,
24, 48, 36 and 60 hours post-transfection, and analyzed in parallel for
luciferase and SEAP activity. Luciferase activity was normalized to the
SEAP control, and mean and standard deviation of triplicate transfec-
tion results are plotted. Two-tailed Student’s T test for comparison of
AA01 to AC01 (p=0.0171) and AA01 to AA01-mu (p=0.0318) were
significant, while comparison of AC01 to AA01-mu revealed no
significant difference.
doi:10.1371/journal.pone.0023673.g003
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initial expansion of the virus upon infection, and lost during
chronic infection, when other factors may play a stronger selective
role. It is possible that during chronic infection a steady-state
develops in viral replication and target cell populations. At this
steady-state, limitations on target cell numbers and immune
susceptibility may play a more important role in viral propagation
than do elements that marginally augment viral infectivity. To
investigate this hypothesis, we used mathematical models to
explore the relationship of viral infectivity to viral load during
early and late infection. Similar ideas of trade offs during the life
history of a population have been developed in ecology as first
proposed by MacArthur and Wilson [34] and are called r/K
selection theory, where r denotes the growth rate of a population
and K denotes the carrying capacity of the environment.
Mathematical models can be used to evaluate the plausibility of
hypotheses about the relationships between different viral and host
characteristics and clinical consequences of infection [35,36].
Previously published models derived by Nowak et al. and by
Stafford et al. have been used to approximate the dynamics of in
vivo SIV and HIV viral load after infection and prior to the
exertion of substantial immunologic pressure [23,24,37]. These
models predict that the initial growth rate of virus should be
exponentially dependent on viral infectivity:
r0~(kp=c)T0{d ð1Þ
where r0 is the exponential viral growth rate before target cells
become rate limiting, and k is the viral infectivity. Other important
factors that govern the initial growth rate of virus include the
number of infectious particles produced per cell (p), the number of
target cells at time zero (T0), and the rates of decay of plasma virus
(c) and infected cells (d).
We used a previously studied data set of viral loads from ten
acutely infected individuals to validate our hypothesis that viral
load increases exponentially with viral infectivity [24]. Using
equation (1) with empirically derived values for the viral
production rate, the viral and infected cell decay rates, and
varying the viral infectivity, we demonstrated that as infectivity
increases, the exponent governing the rate of viral expansion also
increases linearly (Figure 8A). These results suggest that during
initial expansion, if target cell availability is not limiting, viral load
depends exponentially on viral infectivity. This implies a strong
selection pressure early in infection for viruses that have higher
levels of infectivity, although it does not necessarily exclude a
fundamental role for envelope expression levels in the earliest
events of transmission.
During chronic infection, we presumed that virus attained a steady-
state with the rates of viral decay and new viral production being in
balance. Furthermore, we assume that the total number of target cells
remained relatively constant. This is a reasonable first-order
approximation for chronic infection during which total CD4+ Tc e l l
number does not fluctuate significantly over the short term. Under
these approximations, the steady-state viral load, Vss, becomes [24]:
Vss~(pl)=(dc){d=k ð2Þ
Where l represents the renewal rate of uninfected target cells, d is the
death rate of uninfected target cells, and the other variables are as
described for equation 1.We again used a data setfromacutely HIV-1
infected individuals to plot the change in steady-state viral load as a
function of infectivity, k (Figure 8B). One can see from equation (2)
that as the ratio of the uninfected cell death rate, d,t ot h ev i r a l
infectivity, k, increases, the influence of infectivity on steady-state viral
load increases: thus, on the plot, at low values of infectivity, small
changes in infectivity, give rise to substantial changes in steady-state
Figure 4. Pseudovirions bearing leader peptide signature envelopes are more infectious in a single round infectivity assay. HIV-1
pseudovirions were generated by co-transfection of 293T cells with pcDNA 3.1 transmitted envelopes and SG3deltaEnv, a plasmid encoding all HIV-1
structural and accessory proteins except for envelope. SG3deltaEnv and the envelope constructs were transfected at a molar ratio of approximately
four to one. Culture supernatants were collected 24 to 48 hours after transfection, and passed through a 0.2 micron filter. Five-fold serial dilutionso f
supernatants were incubated in 96-well plates with 26104 TZM-bl cells, a reporter cell line expressing HIV-1 co-receptors as well as a Tat-sensitive
luciferase reporter. Pseudovirus and TZM-bl cells were incubated for 48 hours before luciferase activity was quantified. This experiment is
representative of multiple studies. Six basic (dashed lines) and eight non-basic (solid) transmitted envelopes were assayed; position 12 residue is
indicated parenthetically. Relative luciferase activity at each dilution was compared between all basic and non-signature envelopes by Mann-Whitney
test. Dilutions at which p-values for comparison are ,.05 indicated by *, and ,.01 indicated by **.
doi:10.1371/journal.pone.0023673.g004
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viral infectivity, the viral steady-state level plateaus. In the data set
given in Stafford et al. [24] from which our parameter estimates were
derived, the median viral infectivity of the 10 patients studied was
0.65610
26 ml virion
21 day
21, with a maximum estimate of
4.80610
26 ml virion
21 day
21, and minimum estimate of
0.19610
26 ml virion
21 day
21. These values of infectivity all lie well
within the plateau of the curve, implying that, for the range of
infectivity observed in acutely infected individuals, changes in viral
infectivity should not substantially influence steady-state viral load.
Conceptually, these results suggest that at steady state, target cell
populations become limiting, and that under these conditions, the
quantityoffreevirusgovernstheeffectivenesswithwhichthe virusis
able to access these sparse targets. According to this model, viruses
that achieve and sustain higher plasma concentrations are better
able toaccesstargetsthan slowerreplicating ormore quickly cleared
viruses. Infectivity,whichreflects the abilityof a virustocompetefor
a given target cell, does not impart a significant competitive
advantage unless there is very high turnover of uninfected target
cells. We hypothesize that this change in the relevance of infectivity
during early and chronic phases of infection may be responsible for
the importance of the leader peptide signature.
Discussion
In this study, we offer in vitro evidence for the physiologic
function of an HIV-1 signature identified through computational
analyses of acute and chronic envelope sequences undertaken by
Gnanakaran and colleagues. They found histidine to be
significantly enriched at the amino acid 12 position of transmitted
founder envelopes in comparison to chronic envelopes, where this
residue was more likely to mutate to an amino acid other than
histidine. We have demonstrated that the presence of a histidine or
similarly positively charged arginine at this position, in comparison
to non-basic residues, is associated with higher envelope
expression and virion incorporation levels, and may influence
viral infectivity.
These findings add to the growing literature that leader peptides
are not interchangeable shipping labels; rather, they are actively
evolving, protein-specific, regulatory elements, and this is reflected
in the extreme sequence heterogeneity among different leaders
[38]. It has previously been shown that not only do leaders vary in
the efficiency with which they target their proteins to the ER, but
that some leaders mediate context dependent ER trafficking,
directing their messages away from the ER during cellular stress
[29,30,39]. Specifically, the HIV-1 envelope leader peptide has
previously been shown to alter the expression of reporter proteins
to which it has been affixed [17]. We used a secreted luciferase
reporter with differing envelope leader peptides to show that a
change from a basic to a non-basic residue in the positively
charged amino-terminus of the leader altered trafficking efficiency.
Interestingly, the magnitude of difference in luciferase activity
between signature and non-signature leader peptide reporters of
30% (Figure 3) is significantly smaller than the two to three fold
difference in full length envelope protein expression we observed
by Western blot (Figure 2B). One possible explanation for this
Figure 5. Position 12 signature is associated with increased envelope incorporation into pseudovirions. (A) Pseudovirions were
generated in 293T cells, and culture supernatants were layered over 20% sucrose and ultracentrifuged at 27,000 RPM for 2 hours. P24 was quantified
by ELISA (Zeptometrix). (B) Pelleted pseudovirions were normalized for p24, and subsequently analyzed by Western blot using the 3B3 antibody.
doi:10.1371/journal.pone.0023673.g005
HIV Envelope Leader Peptide Signature
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23673difference may be that the position 12 polymorphism has
pleiotropic effects on envelope synthesis, influencing not only
trafficking of nascent protein to the endoplasmic reticulum, but
also affecting the rate of processing within the endoplasmic
reticulum. For example, if a polymorphism delays leader peptide
cleavage, it might slow processivity through the endoplasmic
reticulum, increasing steady-state levels of envelope [17,40]. A
second explanation for the differences in magnitudes observed in
our assays may have to do with the nature of the reporter protein
used in these studies. Luciferase does not undergo the significant
post-translational modification within the ER that envelope
glycoproteins do, and has a much shorter transit time from
initiation of synthesis to the plasma membrane. The prolonged
retention time of envelope within the endoplasmic reticulum may
amplify differences in trafficking efficiency. Overall, our findings
demonstrating the sensitivity of HIV-1 envelope synthesis to
alterations in the leader peptide are consistent with previous
studies that have shown that replacement of the native envelope
Figure 6. Precise quantification of p24 and envelope content in pseudovirions. Fifty milliliter volumes of 293T pseudovirion supernatants
were generated for Envelopes AA01 and AC01. Supernatants were pelleted over a sucrose cushion, and resuspended in PBS. Equal volumes of
resuspended AA01 and AC01 were analyzed by SDS-PAGE. Varying dilutions of a previously quantified virus were run simultaneously. Protein signal
was measured by densitometry, and p24 and envelope in AA01 and AC01 pseudovirus were quantified by comparison to dilutions of known virus.
The ratio of p24 to envelope was calculated for both samples.
doi:10.1371/journal.pone.0023673.g006
Figure 7. Alteration of ratio of pseudovirion p24:envelope does not alter differential pseudovirion incorporation of envelope
between signature and non-signature envelopes. Position 12 histidine bearing envelope AA05 and non-histidine bearing envelope AC02 were
co-transfected with SG3deltaEnv at two different ratios of plasmid DNA to generate pseudovirions in 293T cells. Pseudovirions were purified by
ultracentrifugation over 20% sucrose. Pellets were resupended and analyzed by Western Blot for envelope content and by p24 ELISA for Gag content.
Pelleted pseudovirus was also applied to TZM-bl reporter cells and luciferase activity was measured as an indication of infectivity.
doi:10.1371/journal.pone.0023673.g007
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secretion of envelope [21] [41].
We have shown a strong association between the presence of the
position 12 polymorphism and viral infectivity. This difference in
infectivity correlated with higher levels of signature envelope
incorporation into mature pseudovirions. It has previously been
shown that higher envelope content results in virions with higher
affinity for cellular co-receptors and greater infectivity [41,42,
43,44]. Furthermore, tampering with the HIV-1 envelope leader
peptide in the context of a complete provirus resulted in alterations
in envelope incorporation and changes in virion infectivity [22].
Thus, it is plausible that a position 12 histidine facilitates increased
rates of envelope translation, producing virions with higher levels
of envelope content that are therefore more infectious.
Interestingly, while we were able to abrogate the envelope
translation phenotype by selective mutation of position 12 from
basic to non-basic, we were unable to restore the infectivity
phenotype by selective mutation of position 12. This suggests that
there are other envelope domains that in conjunction with the
position 12 signature contribute to the transmission phenotype.
Thus, the association between position 12 and infectivity may
reflect an association between the signature and other transmis-
sion-associated residues throughout envelope. This hypothesis is
consistent with our observation that the differences in in vitro
infectivity between signature and non-signature viruses are more
dramatic than are either translation or envelope incorporation
differences; there may be more than one mechanism modulating
the infectivity phenotype. Position 12 may be one component of a
larger transmission motif comprised of non-contiguous polymor-
phisms at multiple sites. In order to identify other residues in the
transmission motif, one would need to probe the combined effects
of polymorphisms at position 12 with other signature sites found
by Gnanakaran, et al. Alternatively, it may be possible to identify
functionally linked non-adjacent amino acids using correlation
matrices to assess how disparate regions of the envelope protein
vary in relation to each other, as has recently been done with HIV-
1 Gag [45].
The present study shows that sequence variation at a specific
locus within the envelope leader peptide facilitates virus transmis-
sion and/or propagation in a new host. The ability of amino acid
shifts to mediate crucial transitions in viral ontogeny within the
host has previously been observed with chemokine receptor
tropism [46]: early viruses are almost exclusively CCR5-tropic and
CXCR4 tropism arises later in infection. Just as evolution in viral
cellular tropism may reflect changes in target cell availability,
leader peptide evolution may reflect adaptation from a low viral
load, target cell rich environment to a high virus load, target cell
limited environment. We have modeled the role of viral infectivity
in very early and in steady-state infection. Infectivity may be most
important during the virus ramp up phase when sufficiently
activated target cells are limited. We show, however, that at viral
set-point, the ability of a variant to achieve numerical superiority
through high reproductive rates appears to be more important
than its ability to compete for a limited number of individual target
cells via an enhanced infectivity.
But why might the position 12 signature be preferentially lost
during chronic infection? Lowering envelope expression levels may
be advantageous during chronic infection to escape anti-viral
antibodies. Alternatively, different target cell populations may
respond differently to changes in the signal peptide. The shift from
CCR5 to CXCR4 tropism can potentially be explained by a shift
in target cell populations as the virus expands into new niches. It is
unclear if comparable cell type specificity in the position 12-
determined phenotype plays a role late in infection, and whether
the transmission phenotype may be lost, or become neutral.
Studies of additional HIV-1 envelope signatures, their temporal
and spatial association with the position 12 signature, and their
biological effects will provide a more complete understanding of
the selection pressures faced by the virus during acute and chronic
infection.
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